melanotan aus II (MT-2) MELANOTAN II | Vi Corpus

*Correspondence: Lin Zhang, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Appropriate thyroid assessment and treatment create conditions for peptide effectiveness

*Disclaimer: This product is intended solely for laboratory research purposes

Clinical response is usually evaluated after 8 weeks of use

They are not medicines, are not for human or animal consumption, and are supplied with no dosing or medical guidance

Another peptide called PT-141, which is a metabolite of MT2, is already approved for therapy in women with hypoactive sexual desire disorder (HSDD) [14, 15]